Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 21;62(1):e01453-17.
doi: 10.1128/AAC.01453-17. Print 2018 Jan.

Thrombocytopenia with Tedizolid and Linezolid

Erica Yookyung Lee  1 , Aisling R Caffrey  2   3   4
Affiliations

Thrombocytopenia with Tedizolid and Linezolid

Erica Yookyung Lee et al. Antimicrob Agents Chemother. .

Abstract

Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we observed significantly increased risks of thrombocytopenia of similar magnitudes with both antibiotics: linezolid reporting odds ratio [ROR], 37.9 (95% confidence interval [CI], 20.78 to 69.17); tedizolid ROR, 34.0 (95% CI, 4.67 to 247.30).

Keywords: drug safety; linezolid; pharmacovigilance; tedizolid; thrombocytopenia.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pfizer Inc. 2013. Zyvox package insert. Pfizer Inc., New York, NY.
    1. Cubist Pharmaceuticals. 2014. Sivextro (tedizolid phosphate) package insert. Cubist Pharmaceuticals US, Lexington, MA.
    1. Lodise TP, Fang E, Minassian SL, Prokocimer PG. 2014. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH Clinical trials. Antimicrob Agents Chemother 58:7198–7204. doi:10.1128/AAC.03509-14. - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. 2017. FDA adverse event reporting system (FAERS). U.S. Food and Drug Administration, Silver Spring (MD) http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil... Accessed 21 February 2017.
    1. Sarangdhar M, Tabar S, Schmidt C, Kushwaha A, Shah K, Dahlquist JE, Jegga AG, Aronow BJ. 2016. July 12 Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 34:697–700. doi:10.1038/nbt.3623. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources